WAVEMAN · COMPANY

BIO · Bio-Rad Laboratories, Inc.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

BIO

Name: BIO-RAD LABORATORIES, INC. (BIO) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

BIO-RAD LABORATORIES, INC.

MEDICAL DEVICES · LABORATORY ANALYTICAL INSTRUMENTS · CIK 0000012208

SEC FILINGS☆ WATCH

INSIDER NET · 180D

-$135.6K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

178

13F, latest reported quarter

REVENUE GROWTH

+0.7%

XBRL, annual

NET MARGIN

29.4%

CONVERSIONS · 180D

codes C/M, not in net · $0 priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$135.6K over 180 days

more than 58% of Medical Devices

CONGRESS

no member of Congress has reported trading it

FUNDS

178 funds added or opened last quarter

more than 74% of Medical Devices

REVENUE

+0.7% year over year

below 72% of Medical Devices

MARGIN

29.4% net margin

more than 98% of Medical Devices

BUYBACKS

$79.3M repurchased, FY to 2026-06-30

more than 57% of Medical Devices

SHORT

4.3 days to cover · settled 2026-07-31

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

178 funds added or opened positions in the latest 13F quarter, of 402 holders.

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows a net $135.6K sold by insiders over 180 days, 178 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG DXCM EW TMDX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, BIO-RAD LABORATORIES, INC. insiders sold a net $135.6K of stock across 41 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

ENGELHARDT EVA ANETTE

EVP, President, CDG

SELL

2026-05-11

550.0

$135.6K

BARRY JAMES

EVP, President, LSG

SELL

2025-11-06

699.87

$214.3K

Crowley Michael

EVP, GBL Commercial Operations

SELL

2025-03-14

3,000.0

$741.2K

Last Andrew J.

EVP, Chief Operating Officer

SELL

2024-09-06

3,000.0

$989.8K

BARRY JAMES

EVP, President, LSG

SELL

2024-09-04

623.0

$205.9K

41 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 36 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

First Eagle Investment Management, LLC

5,212,438.0 sh

$1.5B

BlackRock, Inc.

1,698,929.0 sh

$498.8M

DIMENSIONAL FUND ADVISORS LP

944,548.0 sh

$277.3M

VANGUARD CAPITAL MANAGEMENT LLC

826,972.0 sh

$242.8M

ARIEL INVESTMENTS, LLC

816,751.0 sh

$239.8M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Longleaf Partners Fund

$39.3M POSITION · AS OF 2026-03-31

3.7%

Ariel Fund

$92.9M POSITION · AS OF 2026-03-31

3.6%

Ariel Appreciation Fund

$22.6M POSITION · AS OF 2026-03-31

2.6%

Parnassus Value Select ETF

$426.8K POSITION · AS OF 2026-03-31

2.4%

First Trust Health Care AlphaDEX Fund

$19.0M POSITION · AS OF 2026-04-30

2.2%

Buffalo Mid Cap Growth Fund

$2.1M POSITION · AS OF 2026-03-31

1.9%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Executive pay vs shareholder return · Norman Schwartz

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$8.0M

$7.3M

$3.0M

-48%

+5%

2024

$8.3M

$8.6M

$3.1M

-44%

+0%

2023

$7.5M

$1.0M

$2.5M

-45%

+4%

2022

$7.5M

-$5.6M

$2.6M

-28%

+7%

2021

$8.7M

$20.4M

$3.2M

+30%

+39%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$2.6B	$2.6B	$2.7B	$2.8B
GROSS PROFIT	$1.3B	$1.4B	$1.4B	$1.6B
OPERATING INCOME	$47.2M	$269.0M	$337.8M	$482.6M
NET INCOME	$759.9M	$-1.8B	$-637.3M	$-3.6B
EPS (DILUTED)	27.85	-65.36	-21.82	-121.79
OPERATING CASH FLOW	$532.2M	$455.2M	$374.9M	$194.4M
CASH	$529.8M	$488.1M	$403.8M	$434.2M
LONG-TERM DEBT	$1.2B	$1.2B	$1.2B	$1.2B
BUYBACKS	$295.5M	$203.6M	$428.7M	$215.7M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE